Provided by Tiger Trade Technology Pte. Ltd.

Cogent Biosciences, Inc.

34.96
-0.4500-1.27%
Post-market: 34.76-0.2000-0.57%17:50 EDT
Volume:1.90M
Turnover:66.18M
Market Cap:5.67B
PE:-16.19
High:35.14
Open:34.77
Low:34.05
Close:35.41
52wk High:43.73
52wk Low:3.72
Shares:162.31M
Float Shares:143.00M
Volume Ratio:0.69
T/O Rate:1.33%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1600
EPS(LYR):-2.5504
ROE:-73.70%
ROA:-32.93%
PB:10.37
PE(LYR):-13.71

Loading ...

LifeSci Capital Sticks to Their Buy Rating for Cogent Biosciences (COGT)

TIPRANKS
·
Mar 21

Cogent Biosciences Coverage Assumed by Jefferies at Buy

Dow Jones
·
Mar 17

BUZZ-U.S. STOCKS ON THE MOVE-Customers Bancorp, Forgent Power Solutions, Nvidia

Reuters
·
Mar 17

BUZZ-U.S. STOCKS ON THE MOVE-Dollar Tree, Micron, Customers Bancorp

Reuters
·
Mar 16

Cogent Biosciences assumed with a Buy at Jefferies

TIPRANKS
·
Mar 16

BUZZ-Cogent Biosciences rises after US FDA agrees to review rare‑disease drug

Reuters
·
Mar 16

Cogent Biosciences Announces FDA Acceptance Of New Drug Application For Bezuclastinib In Patients With Nonadvanced Systemic Mastocytosis (Nonadvsm)

Reuters
·
Mar 16

Cogent Biosciences Shares Rise 7.2% Premarket After FDA Accepts Application to Review Rare Disease Drug

THOMSON REUTERS
·
Mar 16

Cogent Biosciences: Bezuclastinib Pdufa Target Action Date Set for Dec 30, 2026

THOMSON REUTERS
·
Mar 16

Cogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients With Nonadvanced Systemic Mastocytosis (Nonadvsm)

THOMSON REUTERS
·
Mar 16

U.S. RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Cogent Biosciences, Summit Therapeutics

Reuters
·
Mar 16

Cogent Biosciences Inc : Jefferies Assumes Coverage With Buy Rating; Price Target $55 VS $48

THOMSON REUTERS
·
Mar 16

J.P. Morgan Sticks to Its Buy Rating for Cogent Biosciences (COGT)

TIPRANKS
·
Mar 14

Cogent Biosciences (COGT) Valuation Check After New SUMMIT Trial Results For Bezuclastinib

Simply Wall St.
·
Mar 10

Cogent Biosciences (COGT) Receives a Buy from Stifel Nicolaus

TIPRANKS
·
Mar 03

Analysts Have Conflicting Sentiments on These Healthcare Companies: Cogent Biosciences (COGT), Aquestive Therapeutics (AQST) and Merck & Company (MRK)

TIPRANKS
·
Mar 02

Piper Sandler Keeps Their Buy Rating on Cogent Biosciences (COGT)

TIPRANKS
·
Mar 02

Cogent announces additional results from SUMMIT trial of bezuclastinib

TIPRANKS
·
Mar 02

Cogent Biosciences presents new 48-week SUMMIT trial data for bezuclastinib in NonAdvSM at AAAAI 2026

Reuters
·
Feb 28

Cogent Biosciences Grants Inducement Equity Awards to Three New Employees

Reuters
·
Feb 28